Globus Medical Inc (GMED) concluded trading on Thursday at a closing price of $87.95, with 4.42 million shares of worth about $388.55 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 27.37% during that period and on February 06, 2025 the price saw a loss of about -4.82%. Currently the company’s common shares owned by public are about 113.47M shares, out of which, 112.72M shares are available for trading.
Stock saw a price change of -5.55% in past 5 days and over the past one month there was a price change of 4.79%. Year-to-date (YTD), GMED shares are showing a performance of 6.34% which increased to 69.26% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $49.33 but also hit the highest price of $94.93 during that period. The average intraday trading volume for Globus Medical Inc shares is 1.09 million. The stock is currently trading -3.38% below its 20-day simple moving average (SMA20), while that difference is up 1.74% for SMA50 and it goes to 19.65% higher than SMA200.
Globus Medical Inc (NYSE: GMED) currently have 113.47M outstanding shares and institutions hold larger chunk of about 79.76% of that.
The stock has a current market capitalization of $11.98B and its 3Y-monthly beta is at 1.17. PE ratio of stock for trailing 12 months is 132.67, while it has posted earnings per share of $0.66 in the same period. Its PEG reads 6.92 and has Quick Ratio of 1.64 while making debt-to-equity ratio of 0.13. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for GMED, volatility over the week remained 3.73% while standing at 2.61% over the month.
Stock’s fiscal year EPS is expected to rise by 28.68% while it is estimated to increase by 15.01% in next year. EPS is likely to grow at an annualized rate of 19.17% for next 5-years, compared to annual growth of -7.04% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BofA Securities on January 10, 2025 offering a Neutral rating for the stock and assigned a target price of $97 to it. Coverage by Morgan Stanley stated Globus Medical Inc (GMED) stock as an Overweight in their note to investors on December 02, 2024, suggesting a price target of $100 for the stock. On August 07, 2024, Wells Fargo Upgrade their recommendations, while on May 20, 2024, Piper Sandler Upgrade their ratings for the stock with a price target of $80. Stock get a Buy rating from BTIG Research on March 18, 2024.
